Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Shrinking team NBB
FTE fell two years in a row, from 19.6 to 10.5.
-
Busy address KBO
18 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Celyad Oncology from Mont-Saint-Guibert, company number BE0891118115, closed financial year 2025 with a result of € -564,911 after tax. For that financial year Celyad Oncology recorded revenue of € 21,000 and equity of € 2.2 million. Compared with financial year 2024, the result moved from € -6.4 million to € -564,911. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 10, 2026.
€ 2.2 million
▲ 24% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -564,911
▲ 91 % less loss than in 2024
Profit after tax over the fiscal year.
€ 1.6 million
▼ 25% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -7 million.
People and assets in 2025
10.5
▼ 5.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.8 million
▲ 26% vs 2024
€ 262,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 621,225
▼ 88% vs 2024
Loans from banks and other lenders, long and short.
€ 769,967
▼ 42% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 58 days on average.
€ 140,718
▼ 65% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 1,314,292 | € 102,890 | € 185,510 | € 21,000 | ▼ 89% |
| Profit after taxes | € -39,622,435 | € -24,732,646 | € -6,411,813 | € -564,911 | ▲ € 5.8 million |
| Equity | € 23,154,801 | € 8,216,155 | € 1,804,342 | € 2,239,431 | ▲ 24% |
| Total debts | € 11,328,768 | € 6,776,722 | € 7,101,995 | € 1,716,815 | ▼ 76% |
| Cash | € 11,030,263 | € 2,997,458 | € 2,175,182 | € 1,635,074 | ▼ 25% |
| Retained profit | € -69,082,863 | € -24,732,646 | € -6,411,813 | € -6,976,724 | ▼ € 564,911 |
| Bank debt | € 3,784,023 | € 4,416,115 | € 5,063,157 | € 621,225 | ▼ 88% |
| Balance sheet total | € 34,483,569 | € 14,992,877 | € 8,906,337 | € 4,033,678 | ▼ 55% |
| Employees (FTE) | 65.8 | 19.6 | 15.6 | 10.5 | ▼ 5.1 |
Key figures of Celyad Oncology, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Celyad Oncology?
What happened at Celyad Oncology in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Serge Goblet stepped down as director. NBB
- Christopher Lipuma stepped down as director. NBB
- Marina Udier stepped down as director. NBB
- Matthew Kane stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 564,911. Source: NBB ↗
- CFIP CLYD LLC stepped down as director. NBB
- Jonathan James stepped down as director. NBB
- HILDE WINDELS BV stepped down as director. NBB
In short
From € 39.6 million loss in 2022 to € 564,911 loss in 2025.
Paid € 835 in corporate taxes since 2022.
Pays suppliers within 58 days on average.
A new publication or filing at Celyad Oncology? We notify you, reason included.
Follow Celyad OncologyDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by CFIP CLYD LLC (58.5%) and Tolefi SA (9.4%). It owns 100% of Celyad Inc and 100% of Corquest Medical itself.
Directors
According to the 2025 annual accounts
Serge Goblet
Director
since 2020 · until 2027
Ami Patel Shah
Director
since 2021 · until 2025
CFIP CLYD LLC
Director · represented by Michel Lussier
since 2023 · until 2026
Jonathan James
Director
since 2023 · until 2026
Chairman of the board · represented by Hilde Windels
Also active at: Gimv, MDxHealth, Healis Holding
since 2023 · until 2026
Christopher Lipuma
Director
since 2022 · until 2027
Marina Udier
Director
since 2020 · until 2027
Andrea Gothing
Director
since 2023 · until 2025
Sharon Roberg-Perez
Director
since 2025 · until 2026
Dominic Piscitelli
Director
since 2020 · until 2026
Sage Mandel
Director
since 2023 · until 2026
Matthew Kane
Director, Managing director
since 2024 · until 2027
Shareholders
CFIP CLYD LLC
58.5%
9.4%
Participations
100%
100%
Establishments
Establishment units
Physical locations of this company
Rue Emile Francqui 6
1435 Mont-Saint-Guibert
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 18 companies are registered at this address.
All companies at this address →DERONGY
€ 99,503 gross margin · 2025
3L INTERNATIONAL
€ 221,227 gross margin · 2025
EXYRO
€ 572,448 gross margin · 2025
SYNERGIA MEDICAL
€ -3.1 million gross margin · 2025
DIGITEAL
€ 385,953 gross margin · 2025
+13 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Certifications & Partners
Hosting & Email
Email provider
Microsoft 365
Hosting
GOOGLE - Google LLC, US
Domain
Domain
celyad.com
Registered
2015-02-12
Registrar
IP Twins SAS
Expires
2027-02-12
Website info
Features
Security
Details
- Company number
- 0891.118.115
- VAT number
- BE 0891.118.115
- Registered office
- Rue Emile Francqui 6, 1435 Mont-Saint-Guibert
- Names & denominations
- Celyad Oncology
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 24 July 2007
- Peppol
- Active · Active since 16 Jan 2026
- Contact
- celyad.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige persoonlijke diensten
Overige diensten , n.e.g.